Floatz logo

ONDANSETRON

Alcohol Abuse

University of Texas Southwestern Medical CenterSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Alcohol Abuse cohort.

Asset / SponsorPhaseRating
Escitalopram
University of Texas Southwestern Medical Center
Phase 4BBB
QUETIAPINE
University of Cincinnati
Phase 4BBB
Naltrexone
VA Connecticut Healthcare System
Phase 4BBB
Topiramate
University of California, San Francisco
Phase 4BB
17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL
Sherwood Brown, MD, PhD
Phase 4BB

View all 27 →

Same molecule, other indications

ONDANSETRON is also rated in:

cancer of unknown primary siteDormant
BB
Indicative · Phase 3
71 / 100
View asset →
childhood neoplasmDormant
BB
Indicative · Phase 3
66 / 100
View asset →
lymphomaActive
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →